FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 159 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Study Tackles Key Questions about Liver Transplants for People with Liver... August 24, 2022 How Cancer Survivors Can Overcome Common Challenges of Exercise After Treatment April 12, 2022 Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... October 24, 2022 FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma June 3, 2024 Load more HOT NEWS Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of... Enfortumab Vedotin Approved for Recurrent Bladder Cancer Breast Cancer Vaccine Has Eliminated Cancer In Its First Human Patient
